maxresorb® - innovative biphasic calcium phosphate with two resorption phases

maxresorb®

Synthetic biphasic calcium phosphate
maxresorb® is an innovative, safe, reliable, and fully synthetic bone substitute material that is characterized by controlled resorption properties and outstanding handling characteristics. maxresorb® is composed of 60% hydroxyapatite (HA) and 40% beta-tricalcium phosphate (β-TCP). The unique synthesis-based production process ensures a completely homogenous distribution of both mineral phases.
  • Socket and ridge preservation
  • Ridge augmentation
  • Intrabony defects (1- to 3-wall)
  • Furcation defects (class I-II)
  • Sinus floor elevation
  • Osseous defects

Particle size

The small granules are preferably used in the aesthetic region to give a better surface contouring, while the large particles enable enhanced revascularization of larger defects.

Rehydration

The excellent hydrophilicity of maxresorb® permits rapid rehydration. Rehydration (in blood from the defect or saline solution) is not necessary, but facilitates handling and application, as the wetted granules stick together.

Compression of particles

Avoid excessive compression of the particles during application. Loosely packed particles leave space for blood vessel ingrowth and subsequent formation of new bone matrix.

Re-entry

At least 5 months healing time is recommended to ensure stable integration of particles. For smaller augmentative procedures healing time is generally reduced.

Mixing with autologous bone

Mixing of maxresorb® with autologous bone bring about a biological activity (osteo-inductive and osteo-genetic properties of autologous bone) and support faster regeneration and improved formation of new bone.

botiss maxresorb® and collprotect® membrane for bone splitting - case by Dr J Neugebauer

Surgical presentation of the alveolar ridge with reduced amount of horizontal bone available

Lateral sinus lift with maxresorb® and collprotect® membrane - Dr. Frank Kistler

DVT control after sinusitis surgery, residual bone height 1 mm

Two-stage sinus lift with maxresorb® and collprotect® - Dr. Steffen Kistler

DVT control after sinusitis surgery, residual bone height 1 mm

GBR with maxresorb® and collprotect® membrane - Dr. G. Bayer

DVT image showing the reduced amount of bone available in the area of the mental foramen

Bone augementation with maxresorb® - Dr. R. Cutts

Initial situation: Inflammated tooth #12

  • Synthetic, resorbable, safe and sterile
  • Volume and mechanical graft stability
  • Unique multistep production process
  • Macropores from 200 to 800 μm
  • 60% HA / 40% ß-TCP
  • Osteoconductive
  • Ultra high interconnected porosity
  • Micropores from 1 to 10 μm

Art.-No.

Particle size

Content

20005

0.5-1.0 mm (S)

1x0.5 cc

20010

0.5-1.0 mm (S)

1x1.0 cc

20105

0.8-1.5 mm (L)

1x0.5 cc

20120

0.8-1.5 mm (L)

1x2.0 cc

Art.-No.

Dimensions

Content

21211

20x10x10 mm

1xblock

21221

20x20x10 mm

1xblock

Lateral sinus lift with maxresorb®
Lateral sinus lift with maxresorb®
Sinus lift using maxresorb® mixed with autologous bone - surgery by Dr. A. Pandolfi
Sinus lift using maxresorb® mixed with autologous bone - surgery by Dr. A. Pandolfi
Ice-cone cream technique with maxresorb® and collprotect® – Dr. Alfonso Caiazzo (Italy)
Ice-cone cream technique with maxresorb® and collprotect® – Dr. Alfonso Caiazzo (Italy)
maxresorb® - innovative biphasic calcium phosphate with two resorption phases
maxresorb® - Innovative biphasic calcium phosphate with two resorption phases

The specific composition of maxresorb® promotes the fast formation of new vital bone, ensuring a long-term mechanical and volume stability. The osteoconductivity of maxresorb® is achieved by a matrix of interconnecting pores (with a size ranging between 200 and 800 μm) and a very high porosity of approx. 80%. The high microporosity and nano-structured surface facilitate the uptake and adsorption of blood, proteins, and stem cells. The macropores are ideal for the ingrowth of osteogenic cells and the bony integration.

 

[1] Gauthier et al. Journal of materials science. Ma-terials in medicine, 1999; 10:199–204
[2] Schwartz et al. Journal of materials science. Materials in medicine,1999;10:821–825
[3] Eriberto Bressan et al. PLOS One, 2012, VOl 7, Issue 11; e49146